Apellis Pharmaceuticals Inc. Common Stock
Exchange: NASDAQ
Symbol: APLS
SEC CIK: 0001492422
Phone: 617-977-5700
100 FIFTH AVENUE
WALTHAM MA 02451
CEO: Cedric Francois
|
Price when page updated: 49.47 Date: 2023-11-30
Company Website:
apellis.com
|
_Description: Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
IPO YEAR:
2017
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
5862192279.00
|
Beta:
1.019861465139479
|
52 Week High:
73
|
52 Week Low:
27.5
|
52 Week Change:
-0.11327561327561332
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
87295371
|
Dividend Rate:
0
|
Dividend Yield:
0.00%
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
14 Nov 2022
|
Float:
0
|
return on Equity:
-
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
N/A
|
ttmEPS:
0
|
Revenue:
$423.264M
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
48.50%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
0.70%
|
Return on Assets:
-
|
Return on Capital:
|
Profit Margin:
-
|
Price to Sales:
-
|
Price To Book:
2.74
|
Short Ratio:
3.96
|
PE Ratio:
0
|
Employees:
0
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Apellis Pharmaceuticals Inc. Common Stock [ APLS ].
__Note: Some Links might not have information for the company.
|
|
